Although in our study miR-125b presented a uniform downregulated level in both patient tumor samples and TP53 wild-type and mutant colon cancer cell lines, the therapeutic role of miRNA replacement was observed only in the case of mutant TP53 study models, mutation identified as pathogenic. Here, TP53 is linked to malignant colon neoplasm.